Massimo Martino: Redefining Allogeneic Transplantation in Myelofibrosis
Massimo Martino, President of GITMO, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Hematology Reports, adding:
”We are pleased to inform that our article ‘Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes’ has been published in Hematology Reports as part of the Special Issue Outcomes and Complications Post-Allogeneic Hematopoietic.”
Title: Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes
Authors: Caterina Alati, Stefano Botti, Francesca Cogliandro, Martina Pitea, Matteo Pacilli, Gaetana Porto, Giorgia Policastro, Annalisa Sgarlata, Maria Caterina Mico, Barbara Loteta, Laura Giordano, Giulia Santoro, Jessyca Germano, Massimo Martino
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 15:10Tvisha Subhasish: Extravascular Factor IX Beyond the Circulation
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?